Global Strategy
Kowa's pharmaceutical business is global, with offices in the United States, Europe and Asia. With a commitment to ground-breaking research, development and marketing, we ensure steady supply of products with quality and reliability to help people around the world enjoy better health.
Livalo® is a prescription drug for the treatment of dyslipidemia developed in Japan by Kowa and with its proven efficacy it has grown into our global product currently marketed in the United States and Asia.
Further launches are expected in Europe and other regions in the near future.
USA
Kowa Pharmaceuticals America, Inc.
Sales and marketing
Research and development
Center for Interdisciplinary Cardiovascular Sciences
Research
Europe
Kowa Pharmaceutical Europe AG
Administration center, Research and development
Kowa Pharmaceutical Europe Co. Ltd.
Sales and marketing
Asia
Kowa Pharmaceutical Asia Pte. Ltd.
Administration center, Research and development
Kowa Pharmaceuticals (China) Co., Ltd.
Sales and marketing, Manufacture
Sales and marketing
Sales and marketing
Sales and marketing